Patents by Inventor Jean-Marc Roch

Jean-Marc Roch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090087436
    Abstract: Protein complexes are provided comprising at least one interacting pair of proteins. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes, and in treating and/or preventing diseases and disorders associated with the protein complexes and/or their constituent interacting members.
    Type: Application
    Filed: September 27, 2007
    Publication date: April 2, 2009
    Applicant: Myriad Genetics, Incorporated
    Inventors: Jean-Marc Roch, Karen Heichman
  • Publication number: 20070225209
    Abstract: The present invention generally relates to methods and compositions for treating neurological disorders and diseases. In addition, methods for selecting therapeutic agents useful for treating neurological disorders and diseases are provided.
    Type: Application
    Filed: January 31, 2007
    Publication date: September 27, 2007
    Applicant: Myriad Genetics, Incorporated
    Inventors: Jean-Marc Roch, Paul Bartel, Karen Heichman
  • Patent number: 7229779
    Abstract: A variant human ?7 nicotinic acetylcholine receptor (nAChR) polypeptide is provided wherein the variant contains an amino acid substitution at the valine-274 position of the wild-type human ?7 nAChR. Nucleic acid molecules encoding the variant human ?7 nAChR, vectors and host cells containing such nucleic acid molecules are also provided. In addition, methods are provided for producing the variant as are methods of using such variants for screening compounds for activity at the nAChR.
    Type: Grant
    Filed: December 30, 2003
    Date of Patent: June 12, 2007
    Assignee: Abbott Laboratories
    Inventors: Clark A. Briggs, Murali Gopalakrishnan, David G. Mc Kenna, Lisa M. Monteggia, Jean-Marc Roch, James P. Sullivan, Edward Touma
  • Publication number: 20070087363
    Abstract: The invention provides methods of treating, preventing, delaying the onset, slowing the progression, or reversing the symptoms of Alzheimer's disease and other neurodegenerative diseases characterized by the accumulation of amyloid plaques comprising the A?42 peptide. The invention also provides compounds that reduce the production or secretion of the A?42-peptide by cells, and pharmaceutical compositions comprising such compounds, for the treatment of neurodegenerative diseases characterized by the accumulation of amyloid plaques comprising the A?42 peptide.
    Type: Application
    Filed: September 18, 2006
    Publication date: April 19, 2007
    Applicant: Myriad Genetics, Incorporated
    Inventors: Paul Bartel, Jean-Marc Roch, Janice Sugiyama
  • Patent number: 7015015
    Abstract: The present invention provides an isolated or purified polynucleotide that encodes human endosulfine polypeptide. Isoforms of human endosulfine are also disclosed. The invention also provides methods of making recombinant human endosulfine using the polynucleotides and host cells transformed with the polynucleotides.
    Type: Grant
    Filed: April 2, 2001
    Date of Patent: March 21, 2006
    Assignee: Abbott Laboratories
    Inventors: Jean-Marc Roch, Victoria E. S. Scott, Kristi L. Anderson, James P. Sullivan
  • Publication number: 20050171207
    Abstract: The invention provides compositions and methods for treating neurodegenerative disorders. The method of the invention involves administering to an individual in need of treatment a composition having an R—NSAID and an HMG-CoA reductase inhibitor. The methods and compositions of the invention are useful for treating and preventing neurodegenerative disorders like Alzheimer's disease, dementia, mild cognitive impairment.
    Type: Application
    Filed: March 28, 2005
    Publication date: August 4, 2005
    Applicant: Myriad Genetics, Incorporated
    Inventors: Adrian Hobden, Jean-Marc Roch
  • Publication number: 20040226056
    Abstract: The present invention generally relates to methods and compositions for treating neurological disorders and diseases. In addition, methods for selecting therapeutic agents useful for treating neurological disorders and diseases are provided.
    Type: Application
    Filed: February 9, 2004
    Publication date: November 11, 2004
    Applicant: Myriad Genetics, Incorporated
    Inventors: Jean-Marc Roch, Paul Bartel, Karen Heichman
  • Publication number: 20040203033
    Abstract: A variant human &agr;7 nicotinic acetylcholine receptor (nAChR) polypeptide is provided wherein the variant contains an amino acid substitution at the valine-274 position of the wild-type human &agr;7 nAChR. Nucleic acid molecules encoding the variant human &agr;7 nAChR, vectors and host cells containing such nucleic acid molecules are also provided. In addition, methods are provided for producing the variant as are methods of using such variants for screening compounds for activity at the nAChR.
    Type: Application
    Filed: December 30, 2003
    Publication date: October 14, 2004
    Inventors: Clark A. Briggs, Murali Gopalakrishnan, David G. Mc Kenna, Lisa M. Monteggia, Jean-Marc Roch, James P. Sullivan, Edward Touma
  • Patent number: 6683157
    Abstract: A variant human &agr;7 nicotinic acetylcholine receptor (nAChR) polypeptide is provided wherein the variant contains an amino acid substitution at the valine-274 position of the wild-type human &agr;7 nAChR. Nucleic acid molecules encoding the variant human &agr;7 nAChR, vectors and host cells containing such nucleic acid molecules are also provided. In addition, methods are provided for producing the variant as are methods of using such variants for screening compounds for activity at the nAChR.
    Type: Grant
    Filed: September 18, 2001
    Date of Patent: January 27, 2004
    Assignee: Abbott Laboratories
    Inventors: Clark A. Briggs, Murali Gopalakrishnan, David G. Mc Kenna, Lisa M. Monteggia, Jean-Marc Roch, James P. Sullivan, Edward Touma
  • Patent number: 6653102
    Abstract: The present invention relates to the discovery of protein—protein interactions that are involved in the pathogenesis of neurodegenerative disorders, including Alzheimer's disease (AD). Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of neurodegenerative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.
    Type: Grant
    Filed: October 11, 2001
    Date of Patent: November 25, 2003
    Assignee: Myriad Genetics, Inc.
    Inventors: Jean-Marc Roch, Paul L. Bartel, Karen Heichman, Kimberly Mauck, Max Dufford
  • Publication number: 20030186317
    Abstract: The present invention relates to the discovery of protein-protein interactions that are involved in the pathogenesis of neurodegenerative disorders, including Alzheimer's disease (AD). Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of neurodegenerative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.
    Type: Application
    Filed: October 9, 2001
    Publication date: October 2, 2003
    Applicant: Myriad Genetics, Inc.
    Inventors: Jean-Marc Roch, Paul L. Bartel, Karen Heichman
  • Publication number: 20030073161
    Abstract: A variant human &agr;7 nicotinic acetylcholine receptor (nAChR) polypeptide is provided wherein the variant contains an amino acid substitution at the valine-274 position of the wild-type human &agr;7 nAChR. Nucleic acid molecules encoding the variant human &agr;7 nAChR, vectors and host cells containing such nucleic acid molecules are also provided. In addition, methods are provided for producing the variant as are methods of using such variants for screening compounds for activity at the nAChR.
    Type: Application
    Filed: September 18, 2001
    Publication date: April 17, 2003
    Inventors: Clark A. Briggs, Murali Gopalakrishnan, David G. McKenna, Lisa M. Monteggia, Jean-Marc Roch, James P. Sullivan, Edward Touma
  • Publication number: 20020164655
    Abstract: The present invention relates to the discovery of protein-protein interactions that are involved in the pathogenesis of neurodegenerative disorders, including Alzheimer's disease (AD). Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of neurodegenerative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.
    Type: Application
    Filed: October 11, 2001
    Publication date: November 7, 2002
    Applicant: Myriad Genetics, Inc.
    Inventors: Jean-Marc Roch, Paul L. Bartel, Karen Heichman
  • Publication number: 20020142432
    Abstract: The present invention provides an isolated or purified polynucleotide that encodes human endosulfine polypeptide. Isoforms of human endosulfine are also disclosed. The invention also provides methods of making recombinant human endosulfine using the polynucleotides and host cells transformed with the polynucleotides.
    Type: Application
    Filed: April 2, 2001
    Publication date: October 3, 2002
    Inventors: Jean-Marc Roch, Victoria E.S. Scott, Kristi L. Anderson, James P. Sullivan
  • Publication number: 20020124273
    Abstract: The present invention relates to the discovery of protein-protein interactions that are involved in the pathogenesis of neurodegenerative disorders, including Alzheimer's disease (AD). Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of neurodegenerative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.
    Type: Application
    Filed: October 11, 2001
    Publication date: September 5, 2002
    Inventors: Jean-Marc Roch, Paul L. Bartel, Karen Heichman
  • Publication number: 20020120947
    Abstract: The present invention relates to the discovery of protein-protein interactions that are involved in the pathogenesis of neurodegenerative disorders, including Alzheimer's disease (AD). Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of neurodegenerative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.
    Type: Application
    Filed: September 10, 2001
    Publication date: August 29, 2002
    Applicant: Myriad Genetics, Inc.
    Inventors: Jean-Marc Roch, Paul L. Bartel
  • Publication number: 20020119155
    Abstract: The present invention relates to the discovery of protein-protein interactions that are involved in the pathogenesis of neurodegenerative disorders, including Alzheimer's disease (AD). Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of neurodegenerative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.
    Type: Application
    Filed: October 9, 2001
    Publication date: August 29, 2002
    Applicant: Myriad Genetics, Inc.
    Inventors: Jean-Marc Roch, Paul L. Bartel, Karen Heichman
  • Publication number: 20020119927
    Abstract: The present invention relates to the discovery of protein-protein interactions that are involved in the pathogenesis of neurodegenerative disorders, including Alzheimer's disease (AD). Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of neurodegenerative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.
    Type: Application
    Filed: October 9, 2001
    Publication date: August 29, 2002
    Applicant: Myriad Genetics, Inc.
    Inventors: Jean-Marc Roch, Paul L. Bartel, Karen Heichman
  • Publication number: 20020114799
    Abstract: The present invention relates to the discovery of protein-protein interactions that are involved in the pathogenesis of neurodegenerative disorders, including Alzheimer's disease (AD). Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of neurodegenerative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.
    Type: Application
    Filed: October 10, 2001
    Publication date: August 22, 2002
    Applicant: Myriad Genetics, Inc.
    Inventors: Jean-Marc Roch, Paul L. Bartel, Karen Heichman
  • Publication number: 20020115607
    Abstract: The present invention relates to the discovery of protein-protein interactions that are involved in the pathogenesis of neurodegenerative disorders, including Alzheimer's disease (AD). Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of neurodegenerative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.
    Type: Application
    Filed: October 12, 2001
    Publication date: August 22, 2002
    Applicant: Myriad Genetics, Inc.
    Inventors: Jean-Marc Roch, Paul L. Bartel, Karen Heichman